Oded Icht, Chief Fellow of Radiation Medicine Program at the Princess Margaret Cancer Centre, shared a post on LinkedIn:
“New paper out in Frontiers in Oncology!
CURB-Melanoma has the potential to change how we manage stage 4 melanoma on first-line therapy.
It is a single-arm phase 2 trial for patients who develop oligoprogression, meaning progression in a few spots while the rest of the disease is still controlled. Instead of switching therapy, we treat every progressing lesion with SBRT and keep patients on their current treatment, which is usually more effective than the lines that come after it.
If we can clear the resistant lesions and extend time on an otherwise working regimen, that is a real gain for patients.
Huge thanks to Chiaojung Jillian Tsai for spearheading this trial, and to the medical oncology and radiation oncology teams at Princess Margaret Cancer Centre for making it happen.”
Title: Consolidative use of radiotherapy to block oligoprogression in patients with metastatic melanoma on Systemic Therapy (CURB-Melanoma) – a single arm, phase 2 clinical trial
Authors: Oded Icht, Alexander Sun, Philip Wong, Andrew McPartlin, Thiago Pimentel Muniz, Anna Spreafico, Samuel D. Saibil, J. Nicholas Lukens, Sana D. Karam, John De Almeida, Marcus O. Butler, C. Jillian Tsai
Read the Full Article.
